At Investor Conferences

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

Medigene AG (FSE: MDG1, Prime Standard)

Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit medigene.com About Medigene’s TCR-T Therapy Platform Medigene’s immunotherapies help activate the patient’s own defense mechanisms by harnessing T cells in the battle against cancer. Medigene’s end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, Precision Pairing) and development optimization technologies (e.g. Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2SeventyBio, and Hongsheng Sciences, continue to validate the platform’s assets & technologies. About Medigene’s MDG1015 Program MDG1015 is a 3rd generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1, a well-recognized and validated cancer testis antigen which is expressed in multiple tumor types. MDG1015 contains our high-avidity, NY-ESO-1 TCR combined with our proprietary PD1-41BB co-stimulatory switch receptor that blocks the PD1/PD-L1 inhibitory axis while simultaneously activating the T cell through the well described -41BB pathway further enhancing the activity and persistence of the TCR-T in the hostile tumor microenvironment (TME). MDG1015 is currently undergoing IND/CTA enabling studies. *

 

Period Start 1994-01-01 established
  Group Medigene (Group)
Products Industry pharmaceutical
  Industry 2 TCR engineered T-cells
Persons Person Ho, Selwyn (Medigene 202207– CEO before Connect Biopharma)
  Person 2 Schendel, Dolores J. (Medigene 202207– CSO + Head of RnD before CEO + CMO + Triant + HelmholtzZentrum München)
     
Region Region Martinsried
  Country Germany
  Street 11 Lochhamer Str.
  City 82152 Martinsried
  Tel +49-89-8565-2900
    Address record changed: 2024-01-05
     
Basic data Employees C: 51 to 100 (2020-12-31)
  Currency EUR
  Annual sales 31,247,000 (revenue, consolidated (2022) 2022-12-31)
  Profit -8,330,000 (2022-12-31)
  Cash 22,224,000 (2022-09-30)
     
    * Document for »About Section«: Medigene AG. (2/1/23). "Press Release: Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications". Planegg.
     
   
Record changed: 2023-12-30

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top